- ASSOCIATE PROFESSOR Preventive Medicine
BA, Columbia University
PhD, Yale University
MPH, Columbia University
MS, Yale University
MPhil, Yale University
- William L. Holden, PhD, is an Associate Professor in the Department of Preventive Medicine and serves as Deputy Director of the World Trade Center Health Program Data Center at the Icahn School of Medicine at Mount Sinai. Dr. Holden is an epidemiologist with more than 25 years’ experience in both private and academic settings with a focus on pharmacoepidemiology and occupational epidemiology. Majors contributions in pharmacoepidemiology include developing the first quantitative models for benefit-risk analysis; devising and implementing novel risk management frameworks for both drugs and vaccines; contributing a chapter to the industry standard Council for International Organizations of Medical Sciences (CIOMS) publication on Signal Detection; and shifting the focus from ‘drug safety’ to ‘patient safety’. Contributions in occupational epidemiology include completing numerous analyses of hazardous working conditions whilst an employee of a trade union and as a consultant; developing a method of evaluating the work-relatedness of premature ischemic heart disease; developing exposure standards to foundry fumes for the UK government; and teaching occupational epidemiologic methods and biostatistics to physicians and other professionals. As Deputy Director of the Data Center since 2013, Dr. Holden leads a team of epidemiologists, biostatisticians, and data management specialists, managing and analyzing more than 90 million health-related data points for more than 30,000 WTC responders as part of a long term follow up study. With unparalleled capability and experience in study design, analysis, and data management, the Data Center under Dr. Holden’s leadership is expanding to support research and surveillance in other areas of occupational medicine. Dr. Holden’s current research is focused on further developing benefit-risk analytic methods; incorporating critical thinking principles into epidemiologic studies; the application of Bayesian analytics to occupational health issues; and developing risk communication guidelines as necessary values in health care research. He holds a PhD, MS, and MPhil in epidemiology from Yale University as well as a MPH in epidemiology and a BA from Columbia University.
Carrigan G, Khromava A, Holden W. Changes in the incidence of encephalitis in the UK. Pharmacoepidemiol Drug Saf 2006; 1:S205-6.
Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. The Journal of rheumatology 2004 Oct; 31(10): 1906-11.
Holden WL, Juhaeri J, Dai W. Benefit-risk analysis: examples using quantitative methods. Pharmacoepidemiology and drug safety 2003 Dec; 12: 693-697.
Holden WL, Juhaeri J, Dai W. Benefit-risk analysis: a proposal using quantitative methods. Pharmacoepidemiology and drug safety 2003 Dec; 12: 611-616.
Holden WL. Benefit-risk analysis : a brief review and proposed quantitative approaches. Drug safety 2003; 26(12): 853-62.
Schuster DI, Holden WL, Narula AP, Murphy RB. Irreversible blockade of striatal dopamine receptors in vivo by a derivative of alpha-flupenthixol. European journal of pharmacology 1982 Feb; 77(4).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Holden did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.